Browse all 702 ETFs by category, no search needed
Global 190
US market 67
Country 94
Core UCITS 15
Sector 108
Style & factor 126
Theme 61
Dividend 41
WisdomTree BioRevolution (WDNA) Overvalued or undervalued?
Look-through valuation · Theme · Expense ratio 0.45 % · ISIN US97717Y6187
Price history (since 2021)
Monthly close since 2021. Price shows performance, the valuation verdict is in the look-through above.
WDNA holdings and fair value
| Holding | Weight | vs fair value | Quality |
|---|---|---|---|
| Twist Bioscience Corp TWST | 4.2 % | n/a | n/a |
| Tempus AI, Inc. Class A Common Stock TEM | 3.7 % | n/a | n/a |
| Eli Lilly and Company LLY | 3.6 % | −47.1 % | 67 |
| Natera Inc NTRA | 3.2 % | −94.6 % | 40 |
| Moderna Inc MRNA | 2.8 % | n/a | n/a |
| Immunome Inc IMNM | 2.8 % | −75.8 % | 26 |
| 10X Genomics Inc TXG | 2.6 % | −69.8 % | 64 |
| Thermo Fisher Scientific Inc TMO | 2.3 % | −1.6 % | 62 |
| Stoke Therapeutics Inc STOK | 2.1 % | −46.7 % | 51 |
| United Therapeutics Corporation UTHR | 2.0 % | +32.5 % | 73 |
| Vertex Pharmaceuticals Inc VRTX | 1.8 % | +10.0 % | 79 |
| Gilead Sciences Inc GILD | 1.7 % | +10.0 % | 81 |
| Amgen Inc AMGN | 1.6 % | +10.0 % | 64 |
| Darling Ingredients Inc DAR | 1.6 % | +20.3 % | 51 |
| Beam Therapeutics Inc BEAM | 1.6 % | −63.5 % | 46 |
| Crispr Therapeutics AG CRSP | 1.6 % | −67.0 % | 28 |
| Revolution Medicines Inc RVMD | 1.5 % | n/a | n/a |
| Roivant Sciences Ltd ROIV | 1.5 % | −85.1 % | 44 |
| Krystal Biotech Inc KRYS | 1.4 % | +10.0 % | 72 |
| Vylor Inc. VYLR | 1.4 % | −80.3 % | 67 |
| Prime Medicine, Inc. Common Stock PRME | 1.4 % | −90.5 % | 29 |
| CG Oncology, Inc. Common stock CGON | 1.4 % | −87.4 % | 28 |
| AstraZeneca PLC AZN | 1.4 % | −31.5 % | 70 |
| Pfizer Inc PFE | 1.4 % | −18.5 % | 60 |
| Bayer AG NA BAYN | 1.3 % | +11.4 % | 44 |
Show all 83 holdings
| Holding | Weight | vs fair value | Quality |
|---|---|---|---|
| Biohaven Ltd. BHVN | 1.3 % | n/a | n/a |
| Agios Pharm AGIO | 1.3 % | −54.0 % | 40 |
| Caris Life Sciences, Inc. Common Stock CAI | 1.3 % | −79.3 % | 59 |
| Absci Corp ABSI | 1.2 % | n/a | n/a |
| Novonesis (Novozymes) A/S NSIS-B | 1.2 % | n/a | n/a |
| Novartis AG NOVN | 1.2 % | −8.0 % | 84 |
| Dyne Therapeutics Inc DYN | 1.2 % | −75.1 % | 36 |
| Nurix Therapeutics Inc NRIX | 1.2 % | −83.5 % | 34 |
| Uniqure NV QURE | 1.2 % | n/a | n/a |
| Oruka Therapeutics, Inc. ORKA | 1.2 % | n/a | n/a |
| Xencor Inc XNCR | 1.1 % | −83.8 % | 45 |
| Veracyte Inc VCYT | 1.1 % | +10.7 % | 72 |
| GRAIL, LLC GRAL | 1.1 % | n/a | n/a |
| Structure Therapeutics Inc. American Depositary Shares GPCR | 1.1 % | −18.1 % | 45 |
| Protagonist Therapeutics Inc PTGX | 1.1 % | −91.8 % | 39 |
| BridgeBio Pharma Inc BBIO | 1.0 % | n/a | n/a |
| Intellia Therapeutics Inc NTLA | 1.0 % | −82.6 % | 32 |
| Exelixis Inc EXEL | 1.0 % | +57.3 % | 94 |
| Vir Biotechnology Inc VIR | 1.0 % | −85.6 % | 37 |
| Praxis Precision Medicines Inc PRAX | 1.0 % | n/a | n/a |
| Wave Life Sciences Ltd WVE | 1.0 % | −39.6 % | 23 |
| Rocket Pharmaceuticals Inc RCKT | 1.0 % | −48.0 % | 37 |
| 4D Molecular Therapeutics Inc FDMT | 0.9 % | −54.5 % | 37 |
| Ionis Pharmaceuticals Inc IONS | 0.9 % | n/a | n/a |
| Arrowhead Pharmaceuticals Inc ARWR | 0.9 % | −81.9 % | 52 |
| Repligen Corporation RGEN | 0.9 % | −75.2 % | 66 |
| Halozyme Therapeutics Inc HALO | 0.9 % | +10.0 % | 78 |
| Danaher Corporation DHR | 0.8 % | −9.9 % | 72 |
| argenx NV ADR ARGX | 0.8 % | +1.7 % | 76 |
| Arcturus Therapeutics Holdings Inc ARCT | 0.8 % | −41.3 % | 40 |
| Ideaya Biosciences Inc IDYA | 0.8 % | −81.2 % | 39 |
| Biogen Inc BIIB | 0.8 % | +5.7 % | 61 |
| Alnylam Pharmaceuticals Inc ALNY | 0.8 % | +10.0 % | 68 |
| Illumina Inc ILMN | 0.8 % | +10.0 % | 81 |
| BioNTech SE BNTX | 0.8 % | −45.0 % | 50 |
| Cullinan Oncology LLC CGEM | 0.8 % | −62.4 % | 40 |
| Oxford Nanopore Technologies Ltd ONT | 0.7 % | −87.3 % | 50 |
| Genmab AS GMAB | 0.7 % | +16.4 % | 64 |
| Iovance Biotherapeutics Inc IOVA | 0.7 % | n/a | n/a |
| Editas Medicine Inc EDIT | 0.7 % | n/a | n/a |
| Merck & Company Inc MRK | 0.7 % | −13.6 % | 69 |
| Celldex Therapeutics Inc CLDX | 0.6 % | −82.8 % | 23 |
| Regeneron Pharmaceuticals Inc REGN | 0.6 % | +37.4 % | 73 |
| Syensqo SYENS | 0.6 % | −14.7 % | 47 |
| Viking Therapeutics Inc VKTX | 0.5 % | −81.6 % | 39 |
| Ultragenyx RARE | 0.5 % | n/a | n/a |
| Neuropace Inc NPCE | 0.5 % | n/a | n/a |
| VERBIO Vereinigte BioEnergie AG VBK | 0.5 % | −15.3 % | 69 |
| Nufarm Ltd NUF | 0.5 % | −53.4 % | 42 |
| Qiagen NV QGEN | 0.5 % | −22.6 % | 77 |
| Insmed Inc INSM | 0.5 % | n/a | n/a |
| Zoetis Inc ZTS | 0.5 % | +38.3 % | 79 |
| Biomarin Pharmaceutical Inc BMRN | 0.5 % | +10.0 % | 69 |
| Genus PLC GNS | 0.5 % | +8.8 % | 72 |
| Regenxbio Inc RGNX | 0.4 % | −85.6 % | 41 |
| Green Plains Renewable Energy Inc GPRE | 0.4 % | −31.5 % | 37 |
| Allogene Therapeutics Inc ALLO | 0.4 % | −71.9 % | 32 |
| Geron Corporation GERN | 0.4 % | −69.7 % | 38 |
Fair value and quality per position come from the same valuation as our stock pages. Listing all 83 disclosed positions. "n/a" means we show no value for this position and it does not enter the average.
The 10 most cheaply valued ETFs
Measured against the look-through fair value of the holdings (sufficiently covered funds only). Green means below fair value, red above. Not financial advice.
- 1 KWEB KraneShares CSI China Internet ETF 49.2 % below FV
- 2 CHIQ Global X MSCI China Consumer Disc ETF 49.0 % below FV
- 3 CHIU Global X MSCI China Utilities ETF 43.9 % below FV
- 4 MCHI iShares MSCI China ETF 35.7 % below FV
- 5 FLCH Franklin FTSE China ETF 34.8 % below FV
- 6 FDNI First Trust Dow Jones International Internet ETF 27.3 % below FV
- 7 FCFY First Trust S&P 500 Diversified Free Cash Flow ETF 25.9 % below FV
- 8 ITB iShares U.S. Home Construction ETF 21.3 % below FV
- 9 TAN Invesco Solar ETF 17.3 % below FV
- 10 XLC Communication Services Select Sector SPDR® Fund 16.2 % below FV
Frequently asked about WDNA
Is WDNA overvalued?
What is the fair value of WDNA?
How do you calculate the fair value of an ETF?
Which stocks drive the valuation of WDNA?
Where can I see WDNA holdings with their fair value?
What is the expense ratio of WDNA?
How we value this ETF
An ETF has no fair value of its own like a single stock. We build it bottom up: every holding has a fair value and a quality score on our pages. Weighted by portfolio share, that gives WisdomTree BioRevolution Fund an average of how cheap or expensive its companies currently sit versus fair value, and how high their average quality is.
As of: Nov 2, 2026
The look-through is a computed summary of public fundamentals and is no substitute for your own research.